Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.

Lauschke VM, Ingelman-Sundberg M.

Eur J Pharm Sci. 2019 Mar 15;130:65-77. doi: 10.1016/j.ejps.2019.01.024. Epub 2019 Jan 23.

PMID:
30684656
2.

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Lauschke VM, Zhou Y, Ingelman-Sundberg M.

Pharmacol Ther. 2019 Jan 22. pii: S0163-7258(19)30008-7. doi: 10.1016/j.pharmthera.2019.01.002. [Epub ahead of print] Review.

3.

AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis.

Cordero-Herrera I, Kozyra M, Zhuge Z, McCann Haworth S, Moretti C, Peleli M, Caldeira-Dias M, Jahandideh A, Huirong H, Cruz JC, Kleschyov AL, Montenegro MF, Ingelman-Sundberg M, Weitzberg E, Lundberg JO, Carlstrom M.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):217-226. doi: 10.1073/pnas.1809406115. Epub 2018 Dec 17.

4.

Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury.

Copple IM, den Hollander W, Callegaro G, Mutter FE, Maggs JL, Schofield AL, Rainbow L, Fang Y, Sutherland JJ, Ellis EC, Ingelman-Sundberg M, Fenwick SW, Goldring CE, van de Water B, Stevens JL, Park BK.

Arch Toxicol. 2019 Feb;93(2):385-399. doi: 10.1007/s00204-018-2354-1. Epub 2018 Nov 13.

5.
6.

Human hepatic 3D spheroids as a model for steatosis and insulin resistance.

Kozyra M, Johansson I, Nordling Å, Ullah S, Lauschke VM, Ingelman-Sundberg M.

Sci Rep. 2018 Sep 24;8(1):14297. doi: 10.1038/s41598-018-32722-6.

7.

Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells.

Baze A, Parmentier C, Hendriks DFG, Hurrell T, Heyd B, Bachellier P, Schuster C, Ingelman-Sundberg M, Richert L.

Tissue Eng Part C Methods. 2018 Sep;24(9):534-545. doi: 10.1089/ten.TEC.2018.0134.

PMID:
30101670
8.

Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays.

Ingelman-Sundberg M, Lauschke VM.

Toxicol Sci. 2018 Sep 1;165(1):4-5. doi: 10.1093/toxsci/kfy160. No abstract available.

PMID:
30063796
9.

Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions.

Ingelman-Sundberg M, Lauschke VM.

Pharmacogenomics. 2018 Sep 1;19(14):1133-1138. doi: 10.2217/pgs-2018-0096. Epub 2018 Jul 25.

PMID:
30041575
10.

Functional characterization of CYP2D7 gene variants.

Jukic MM, Lauschke VM, Saito T, Hiratsuka M, Ingelman-Sundberg M.

Pharmacogenomics. 2018 Aug 1;19(12):931-936. doi: 10.2217/pgs-2018-0065. Epub 2018 Jul 24.

PMID:
30040020
11.

Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent.

Parmentier C, Hendriks DFG, Heyd B, Bachellier P, Ingelman-Sundberg M, Richert L.

Toxicol Lett. 2018 Oct 1;295:187-194. doi: 10.1016/j.toxlet.2018.06.1069. Epub 2018 Jun 18.

PMID:
29913214
12.

Integrating rare genetic variants into pharmacogenetic drug response predictions.

Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM.

Hum Genomics. 2018 May 25;12(1):26. doi: 10.1186/s40246-018-0157-3.

13.

Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.

Vorrink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM.

Toxicol Sci. 2018 Jun 1;163(2):655-665. doi: 10.1093/toxsci/kfy058.

14.

Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study.

Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, Schofield C, Baze A, Foster AJ, Williams DP, van de Ven AWM, Jacobs F, Houdt JV, Lähteenmäki T, Snoeys J, Juhila S, Richert L, Ingelman-Sundberg M.

Toxicol Sci. 2018 Apr 1;162(2):655-666. doi: 10.1093/toxsci/kfx289.

15.

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.

Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M.

Am J Psychiatry. 2018 May 1;175(5):463-470. doi: 10.1176/appi.ajp.2017.17050550. Epub 2018 Jan 12.

PMID:
29325448
16.

How to Consider Rare Genetic Variants in Personalized Drug Therapy.

Lauschke VM, Ingelman-Sundberg M.

Clin Pharmacol Ther. 2018 May;103(5):745-748. doi: 10.1002/cpt.976. Epub 2018 Jan 5.

PMID:
29313952
17.

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.

Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodríguez-Antona C.

Genet Med. 2018 Jun;20(6):622-629. doi: 10.1038/gim.2017.156. Epub 2017 Oct 26.

PMID:
29261188
18.

Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Lauschke VM, Milani L, Ingelman-Sundberg M.

AAPS J. 2017 Nov 27;20(1):4. doi: 10.1208/s12248-017-0161-x. Review.

PMID:
29181807
19.

The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.

Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE; PharmVar Steering Committee.

Clin Pharmacol Ther. 2018 Mar;103(3):399-401. doi: 10.1002/cpt.910. Epub 2017 Nov 14.

20.

Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities.

Lauschke VM, Barragan I, Ingelman-Sundberg M.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:161-185. doi: 10.1146/annurev-pharmtox-010617-053021. Epub 2017 Oct 13.

PMID:
29029592
21.

Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.

Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J, Hornberg E, Ingelman-Sundberg M, Jang KJ, Jones DR, Lauschke VM, Marx U, Mettetal JT, Pointon A, Williams D, Zimmermann WH, Newham P.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:65-82. doi: 10.1146/annurev-pharmtox-010617-052722. Epub 2017 Oct 13.

PMID:
29029591
22.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
23.

Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy.

Lauschke VM, Ivanov M, Ingelman-Sundberg M.

Trends Pharmacol Sci. 2017 Sep;38(9):765-770. doi: 10.1016/j.tips.2017.05.007. Epub 2017 Jun 15. No abstract available.

PMID:
28625497
24.

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ, Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M.

Mol Psychiatry. 2017 Aug;22(8):1224. doi: 10.1038/mp.2017.93. Epub 2017 Apr 18.

PMID:
28416806
25.

Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO).

Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB.

Acta Pharm Sin B. 2017 Mar;7(2):241-248. doi: 10.1016/j.apsb.2016.12.006. Epub 2017 Feb 1.

26.

Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.

Zhou Y, Ingelman-Sundberg M, Lauschke VM.

Clin Pharmacol Ther. 2017 Oct;102(4):688-700. doi: 10.1002/cpt.690. Epub 2017 May 26.

27.

Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics.

Vorrink SU, Ullah S, Schmidt S, Nandania J, Velagapudi V, Beck O, Ingelman-Sundberg M, Lauschke VM.

FASEB J. 2017 Jun;31(6):2696-2708. doi: 10.1096/fj.201601375R. Epub 2017 Mar 6.

28.

Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.

Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, Ingelman-Sundberg M.

Drug Metab Dispos. 2017 Apr;45(4):419-429. doi: 10.1124/dmd.116.074369. Epub 2017 Jan 30.

29.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Erratum in: Clin Pharmacol Ther. 2017 Jul;102(1):152.

PMID:
28027596
30.

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ, Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M.

Mol Psychiatry. 2017 Aug;22(8):1155-1163. doi: 10.1038/mp.2016.204. Epub 2016 Nov 29. Erratum in: Mol Psychiatry. 2017 Aug;22(8):1224.

PMID:
27895323
31.

The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration.

Lauschke VM, Mkrtchian S, Ingelman-Sundberg M.

Biochem Biophys Res Commun. 2017 Jan 15;482(3):399-407. doi: 10.1016/j.bbrc.2016.10.084. Epub 2016 Oct 24. Review.

PMID:
27789285
32.

Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.

Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Young RS, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK.

Hepatology. 2017 Feb;65(2):710-721. doi: 10.1002/hep.28886. Epub 2016 Nov 30. Review.

33.

Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation.

Lauschke VM, Vorrink SU, Moro SM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R, Park BK, Goldring CE, Ellis E, Johansson I, Mkrtchian S, Andersson TB, Ingelman-Sundberg M.

Hepatology. 2016 Nov;64(5):1743-1756. doi: 10.1002/hep.28780. Epub 2016 Sep 30.

PMID:
27532775
34.

Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability.

Hendriks DF, Fredriksson Puigvert L, Messner S, Mortiz W, Ingelman-Sundberg M.

Sci Rep. 2016 Oct 19;6:35434. doi: 10.1038/srep35434.

35.

The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.

Lauschke VM, Ingelman-Sundberg M.

Int J Mol Sci. 2016 Oct 12;17(10). pii: E1714. Review.

36.

Ensuring the Quality of Stem Cell-Derived In Vitro Models for Toxicity Testing.

Stacey GN, Coecke S, Price AB, Healy L, Jennings P, Wilmes A, Pinset C, Ingelman-Sundberg M, Louisse J, Haupt S, Kidd D, Robitski A, Jahnke HG, Lemaitre G, Myatt G.

Adv Exp Med Biol. 2016;856:259-297. Review.

PMID:
27671727
37.

Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates.

Lauschke VM, Hendriks DF, Bell CC, Andersson TB, Ingelman-Sundberg M.

Chem Res Toxicol. 2016 Dec 19;29(12):1936-1955. Epub 2016 Sep 23. Review.

PMID:
27661221
38.

Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ.

Arch Toxicol. 2016 Dec;90(12):2979-3003. Epub 2016 Sep 22. Review.

39.

Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas.

Nolé P, Duijndam B, Stenman A, Juhlin CC, Kozyra M, Larsson C, Ingelman-Sundberg M, Johansson I.

PLoS One. 2016 Sep 6;11(9):e0162379. doi: 10.1371/journal.pone.0162379. eCollection 2016.

40.

A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity.

Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, Gerets HHJ, Labbe G, Hoët D, Dorau M, Schofield CA, Lovatt CA, Holder JC, Stahl SH, Richert L, Kitteringham NR, Jones RP, Elmasry M, Weaver RJ, Hewitt PG, Ingelman-Sundberg M, Goldring CE, Park BK.

Arch Toxicol. 2017 Mar;91(3):1385-1400. doi: 10.1007/s00204-016-1745-4. Epub 2016 Jun 25.

41.

The CYP2W1 enzyme: regulation, properties and activation of prodrugs.

Guo J, Johansson I, Mkrtchian S, Ingelman-Sundberg M.

Drug Metab Rev. 2016 Aug;48(3):369-78. doi: 10.1080/03602532.2016.1188939. Epub 2016 Jun 3. Review.

PMID:
27257736
42.

Requirements for comprehensive pharmacogenetic genotyping platforms.

Lauschke VM, Ingelman-Sundberg M.

Pharmacogenomics. 2016 Jun;17(8):917-24. doi: 10.2217/pgs-2016-0023. Epub 2016 Jun 1. Review.

PMID:
27248710
43.

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.

Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers AC, Jacobs F, Snoeys J, Sison-Young RL, Jenkins RE, Nordling Å, Mkrtchian S, Park BK, Kitteringham NR, Goldring CE, Lauschke VM, Ingelman-Sundberg M.

Sci Rep. 2016 May 4;6:25187. doi: 10.1038/srep25187.

44.

Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression.

Ivanov M, Kals M, Lauschke V, Barragan I, Ewels P, Käller M, Axelsson T, Lehtiö J, Milani L, Ingelman-Sundberg M.

Nucleic Acids Res. 2016 Aug 19;44(14):6756-69. doi: 10.1093/nar/gkw316. Epub 2016 Apr 29.

45.

Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.

Kozyra M, Ingelman-Sundberg M, Lauschke VM.

Genet Med. 2017 Jan;19(1):20-29. doi: 10.1038/gim.2016.33. Epub 2016 Apr 21.

PMID:
27101133
46.

High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis.

Pradip A, Steel D, Jacobsson S, Holmgren G, Ingelman-Sundberg M, Sartipy P, Björquist P, Johansson I, Edsbagge J.

Stem Cells Int. 2016;2016:2475631. doi: 10.1155/2016/2475631. Epub 2016 Jan 5.

47.

Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?

Ingelman-Sundberg M, Cascorbi I.

Clin Pharmacol Ther. 2016 May;99(5):478-80. doi: 10.1002/cpt.351. Epub 2016 Mar 29.

PMID:
26874931
48.

Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1.

Guo J, Thiess S, Johansson I, Mkrtchian S, Ingelman-Sundberg M.

FEBS Lett. 2016 Feb;590(3):330-9. doi: 10.1002/1873-3468.12063. Epub 2016 Feb 2.

49.

Precision Medicine and Rare Genetic Variants.

Lauschke VM, Ingelman-Sundberg M.

Trends Pharmacol Sci. 2016 Feb;37(2):85-86. doi: 10.1016/j.tips.2015.10.006. Epub 2015 Dec 17. No abstract available.

PMID:
26705087
50.

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM.

Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20. Review.

Supplemental Content

Loading ...
Support Center